Fate Therapeutics Inc (FATE)

전일 마감가:

$3.87

열려 있는:

$3.88

하루 거래량:

2.73M

시가총액:

$432.38M

수익:

$63.53M

순이익/손실:

$-160.93M

주가수익비율:

-1.7512

EPS:

-2.17

순현금흐름:

$-138.42M

1주 성능:

-20.67%

1개월 성능:

-44.61%

6개월 성능:

+117.14%

1년 성능:

-34.71%

1일 변동 폭

$3.74

$3.95

52주 변동 폭

$1.63

$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

명칭

Fate Therapeutics Inc

부문

Healthcare (1191)

산업

Biotechnology (688)

전화

858-875-1800

주소

3535 General Atomics Court, Suite 200, San Diego, CA

직원

80

트위터

@fatethx

다음 수익 날짜

2024-05-01

최신 SEC 제출 서류

FATE's Discussions on Twitter

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-27	재개	Wells Fargo	Equal Weight
2023-01-24	다운그레이드	H.C. Wainwright	Buy → Neutral
2023-01-06	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2023-01-06	다운그레이드	BofA Securities	Buy → Underperform
2023-01-06	다운그레이드	Cowen	Outperform → Market Perform
2023-01-06	다운그레이드	Piper Sandler	Overweight → Neutral
2023-01-06	다운그레이드	Stifel	Buy → Hold
2023-01-06	다운그레이드	Truist	Buy → Hold
2023-01-06	다운그레이드	Wedbush	Outperform → Neutral
2023-01-03	다운그레이드	Guggenheim	Buy → Neutral
2022-12-22	다운그레이드	Oppenheimer	Outperform → Perform
2022-12-15	개시	Goldman	Sell
2022-11-04	재개	Cantor Fitzgerald	Overweight
2022-10-10	개시	Canaccord Genuity	Buy
2022-08-18	재개	Wells Fargo	Overweight
2022-07-28	개시	Needham	Hold
2022-07-11	업그레이드	BMO Capital Markets	Market Perform → Outperform
2022-06-03	개시	Robert W. Baird	Neutral
2022-02-11	재개	BMO Capital Markets	Market Perform
2021-12-15	업그레이드	Wedbush	Neutral → Outperform
2021-12-07	개시	Cowen	Outperform
2021-11-09	업그레이드	Citigroup	Neutral → Buy
2021-08-26	개시	Morgan Stanley	Equal-Weight
2021-06-07	업그레이드	H.C. Wainwright	Neutral → Buy
2021-05-07	업그레이드	Wedbush	Neutral → Outperform
2021-04-26	재개	Jefferies	Buy
2021-02-26	개시	BofA Securities	Buy
2021-02-26	다운그레이드	Wedbush	Outperform → Neutral
2021-02-11	다운그레이드	Citigroup	Buy → Neutral
2021-01-27	재개	H.C. Wainwright	Neutral
2020-05-13	개시	H.C. Wainwright	Buy
2020-03-04	개시	Barclays	Overweight
2020-01-09	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2019-12-30	재확인	Mizuho	Buy
2019-12-09	업그레이드	Wells Fargo	Market Perform → Outperform
2019-11-12	개시	SunTrust	Buy
2019-11-06	다운그레이드	Wells Fargo	Outperform → Market Perform
2019-10-01	개시	Stifel	Buy
2019-08-09	개시	BTIG Research	Buy
2019-07-22	개시	Cantor Fitzgerald	Overweight
2019-07-12	개시	Oppenheimer	Outperform
2019-06-13	개시	Mizuho	Buy
2019-06-07	개시	ROTH Capital	Neutral
2019-05-31	개시	Guggenheim	Buy
2019-05-24	재개	Citigroup	Buy
2019-03-28	개시	SVB Leerink	Outperform
2019-01-03	다운그레이드	Stephens	Overweight → Equal-Weight
2018-11-05	개시	Jefferies	Buy
2018-08-01	개시	Citigroup	Buy
2018-03-06	다운그레이드	H.C. Wainwright	Buy → Neutral

모두보기

Fate Therapeutics Inc 주식(FATE)의 최신 뉴스

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

GlobeNewswire Inc.

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Zacks Investment Research

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Zacks Investment Research

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

Zacks Investment Research

Novartis (NVS) to Report Q1 Earnings: What to Expect?

Zacks Investment Research

What's in Store for Biogen (BIIB) This Earnings Season?

Zacks Investment Research

Fate Therapeutics Inc (FATE) 재무 분석

Fate Therapeutics Inc (FATE) 매출 2024

Fate Therapeutics Inc (FATE) 순이익 2024

Fate Therapeutics Inc (FATE) 현금흐름 2024

Fate Therapeutics Inc (FATE) 주당 순이익 2024